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Background and Objective: With a phase 3 clinical trial (EF-32, ClinicalTrials.gov: NCT04471844)
currently underway examining the potential benefit of concurrent chemoradiation and tumor treating fields
(TTFields) for patients with glioblastoma (GBM), we present the following narrative review to highlight
the current evidence that supports this approach. The current management paradigm for GBM includes
maximal safe surgical resection followed by concurrent chemoradiation with further temozolomide (TMZ)
and TTFields used as maintenance therapy. Despite several treatment advances over the past few decades,
the overall prognosis remains poor and new strategies are currently under investigation, including the use of
chemoradiation concurrently with TTFields.
Methods: In this review, we will discuss the preclinical and clinical work that has been performed
combining both TTFields with radiation. We performed a narrative review of peer-reviewed articles related
to the management of glioblastoma with regard to concurrent chemoradiation and TTFields and synthesized
the data in the context of our clinical experience and practice. PubMed, Medline, Embase, Cochrane Library,
and various center-specific guidelines were searched for literature regarding concurrent chemoradiation with
TTFields for patients with GBM.
Key Content and Findings: Driven by preclinical studies demonstrating the synergy between TTFields
and radiation, more recent clinical work has been performed and has shown that combining treatment is
both feasible and tolerable.
Conclusions: In this review, we will discuss the mechanism of action which TTFields and radiation
share, as well as discuss the toxicities of combining therapy in patients with GBM. Based on institutional
experiences, we will highlight treatment techniques, including scalp sparing methodology and modified
computed tomography (CT) simulation workflow, when concurrent TTFields and radiation are given.
Lastly, we will provide discuss management considerations, specifically scalp prophylactic interventions and
treatments, when using concurrent TTFields with chemoradiation.
Keywords: Tumor treating fields (TTFields); glioblastoma; concurrent therapy; radiotherapy; scalp-sparing
radiation
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Introduction
Glioblastoma (GBM) is the most common subtype of
primary malignant brain tumors in adults (1). Despite several
treatment advances over the past few decades, the overall
prognosis remains poor and new strategies are currently
under investigation, including the use of tumor treating fields
(TTFields) concurrently with chemoradiation (2,3).
The current management paradigm for glioblastoma
(GBM) includes maximal safe surgical resection followed
by concurrent chemoradiation with further temozolomide
(TMZ) and TTFields used as maintenance therapy as
defined by several landmark, randomized clinical trials
(4-7). TMZ, when given both concurrently and as part
of maintenance therapy, showed improvements in both
progression-free survival (PFS) and overall survival (OS)
(4,5). Patients with and without O 6 -methylguanineDNA-methyltransferase (MGMT) silencing, a prognostic
indicator, benefit with receipt of TMZ, although with
more improved results in the methylated subgroup (8).
Although initially approved for the treatment of recurrent
and refractory GBM, TTFields soon became a part of
maintenance therapy based on the significant improvements
in PFS and OS observed in patients receiving concurrent
chemoradiation (6,7). TTFields uses low-intensity,
intermediate frequency (200 kHz) alternating electric fields
to disrupt cellular processes including proliferation and
replication (9,10). Due to the significant benefit observed
with maintenance TTFields, several preclinical and clinical
studies have investigated whether concurrent treatment
offers a synergistic and feasible strategy. Given the growing
evidence showing safety of combining radiation with
TTFields in patients with GBM, as well as the currently
enrolling phase 3, randomizing clinical trial (EF-32;
NCT04471844) aimed at determining the clinical benefit of
this approach, we have put together the following narrative
review to highlight the work that has been done in this
space.
In this review, we will discuss the preclinical work which
demonstrates the complexity of the mechanisms by which
TTFields operates and the significant interplay between
TTFields and radiotherapy. We will review the clinical
studies that have been performed which demonstrate the
safety and feasibility of utilizing a combination approach.
Lastly, we will review treatment techniques, including scalp
sparing methodology and modified computed tomography
(CT) simulation workflow. We present the following
article in accordance with the Narrative Review reporting
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checklist (available at https://cco.amegroups.com/article/
view/10.21037/cco-22-90/rc).
Methods
PubMed, Medline, Embase, Cochrane Library, and various
center-specific guidelines were searched for literature
regarding concurrent chemoradiation with TTFields for
patients with GBM on August 1, 2022 (Table 1). Databases
were searched using combinations of TTFields, radiation,
and GBM based on both MeSH headings and text
words. MeSH terms used included, but were not limited
to, “TTFields”, “glioblastoma”, “concurrent therapy”,
“radiotherapy”, “preclinical”, “clinical”, “scalp”, “toxicity”,
“feasibility”, and “safety” in various combinations. Titles
and abstracts were screened for relevant articles and
studies. References from full-text articles were screened for
additional studies. All co-authors contributed, reviewed, and
approved the selected literature for this review.
Preclinical data
A major target for TTFields, which is shared by
radiotherapy, is DNA. DNA fragmentation resulting in
reduced clonogenicity has been reported in pancreatic cells
exposed to TTFields (11-13). Radiotherapy, like TTFields,
also disrupts the cell division machinery (14). These
commonalities set the stage for a synergistic interaction
between the two treatment modalities.
Mitotic catastrophic rate is defined as the rate of
microtubule polymerization and depolymerization during
mitosis. Radiation therapy (RT) stresses target cells, causing
an unbalanced catastrophic rate and an inappropriate entry of
cells into mitosis, which consequently causes cell death (15).
Such unbalanced catastrophic rates and mitotic abnormalities
have also been ascribed to TTFields by various studies (9,10).
These similarities in mechanisms of action led an in vivo study
to apply TTFields for 24 hours followed immediately by
RT to doses ranging between 2 and 6 Gy to human GBM
cell lines (9). This resulted in cells with multi-nucleation
phenotypes and mono- and multi-polar spindle structures,
events that led to a catastrophic rate that was significantly
greater than that achieved by either treatment modality on
its own. In addition, they demonstrated a blockade of DNA
repair and decreased glioma cell survival, thus suggesting
that TTFields radiosensitizes cancer cells.
Such synergy was duplicated by another in vivo study
that reversed the sequence of treatment, applying TTFields
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Table 1 Methods for selection of literature included in this review
Items

Specification

Date of search

August 1, 2022

Databases and other sources searched

PubMed, Medline, Embase, Cochrane Library, center-specific guidelines

Search terms used

TTFields, tumor treating fields, glioblastoma, concurrent therapy, radiotherapy, preclinical,
clinical, scalp, toxicity, feasibility, safety

Timeframe

All studies obtained were from 2000–current

Inclusion and exclusion criteria

All studies included were available in English language. Clinical studies involving concurrent
TTFields with radiation must have explicitly stated that both treatments were provided at
the same time

Selection process

All authors contributed and reviewed the selected literature

for 72 hours after RT to glioma cell lines (10). In contrast
to the previous study, this particular treatment sequence did
not impact the early steps of damage recognition and repair,
as evidenced by unchanged levels of γ-H2AX between
the combination treatment or treatment with TTFields
or RT only. Moreover, the non-homologous end joining
response with the sequential treatment was also unchanged
from the response from RT alone. However, RAD51 foci
formation was increased for 24 hours after irradiated cells
were exposed to TTFields, which signals a disruption
of the homologous recombination repair pathway. This
consequently resulted in a significantly reduced cell survival
with the combination treatment and showed that in vitro,
TTFields improved radiation efficacy by inhibiting or
delaying DNA damage repair
The synergy between RT and TTFields regardless of
their application sequence could mean that subjecting
GBM cells to TTFields while undergoing RT may similarly
potentiate the desired cytotoxicity as compared to RT
alone.

Several clinical trials have investigated the safety and
efficacy of the concurrent tri-modality therapy. Currently,
two pilot trials evaluated the safety and feasibility of
concurrent TTFields and radiation (2,3). A pilot trial by
Bokstein et al. demonstrated the feasibility and safety of
TTFields administered concurrently with radiation and
TMZ in GBM (2). In this study, patients received standard
daily TMZ (75 mg/m2 daily) together with radiation at total
dose of 60 Gy given in 30 fractions. TTFields were applied
during the radiotherapy period (and continued use after

for up to 24 months or second disease progression) starting
within 1 week of the radiotherapy treatment start date. The
electrode array in this study was removed during the actual
radiation treatment. After clinical and radiological evaluation
of treatment response was performed approximately
4 weeks after the end of RT with TTFields and TMZ,
patients eligible for adjuvant treatment started monthly
TMZ combined with TTFields treatment. 10 total patients
were enrolled with a median Karnofsky performance score
(KPS) of 90 and 5 (50%) underwent biopsy only. Adverse
effects (AEs) with the combined therapies were evaluated.
The most common AE related to TTFields treatment
was skin toxicity, reported in 8 (80%) patients, and was of
low severity (Common Terminology Criteria for Adverse
Events, or CTCAE version 5.0, grade 1–2). Skin reactions
included application site erythema, erosions, blisters,
dermatitis, seborrheic keratosis, eczema, and pruritus in
the skin areas covered by the transducer arrays. No delays
in radiotherapy were related to TTFields treatment. No
severe AEs (CTCAE grade ≥3) were attributed to TTFields
treatment. Preliminary data from the study showed a
median PFS of 8.9 months.
A separate pilot study was conducted which enrolled 30
patients (3). Patients received concurrent chemoradiotherapy
(75 mg/m2 daily with 60 Gy in 30 fractions) and TTFields
with radiation treatment delivered through the TTFields
arrays. Median KPS was 90, 18 (60%) patients had a
subtotal resection and 12 (40%) patients had multifocal
disease at presentation. Skin adverse events were noted in
25 (83.3%) of patients and were limited to CTCAE grade
1–2. No grade 3 or higher adverse events were noted. The
primary endpoint of the study was met and no TTFields
discontinuation occurred due to high grade scalp toxicity.
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Table 2 Pros and cons of delivering radiation treatment with and without TTFields arrays in place
Pros/cons Radiation with TTFields arrays in place

Radiation with TTFields arrays off at time of treatment

Pros

Minimize interruption leads to better synergy with radiation

No bolus effect at time of treatment

Minimize physical scalp injury or irritation with daily array changes

No radiation dosimetry changes

Compliance improved with less frequent changing

No radiation workflow changes
IGRT more straightforward

Cons

Dosimetric considerations (bolus effect increases scalp dose, mild/
negligible PTV dosimetry changes)

Daily array removal may lead to physical scalp injury

Need modification of standard radiation simulation workflow

Interruption of treatment leads to loss of optimal synergy
with radiation

Imaging artifact on CBCT image guidance, requiring kV-kV imaging
guidance

Potential for poorer compliance and reduced daily usage

TTFields, tumor treating fields; IGRT, image-guided radiation therapy; PTV, planning target volume; CBCT, cone beam computed
tomography.

There was negligible change in mental status or quality of
life between baseline and the concurrent phase of treatment
as measured by a Mini-Mental State Examination (MMSE),
EORTC Core Quality of Life questionnaire (QLQ-C30
version 3), and a brain cancer-specific health-related quality
of life questionnaire (QLQ-BN20). The median PFS was
9.3 months.
As evidenced by these two pilot studies, the most
common toxicity of concurrent radiation with TTFields is
scalp dermatitis, and therefore, caution must be considered
with regard to skin dose. Scalp sparing techniques, as well
as additional treatment considerations are discussed below.

duration for TTFields usage, alternative strategies have
been suggested which allow patients to maintain electrode
arrays in place during daily radiotherapy treatments. The
benefits and consequences of radiation being delivered with
TTFields arrays in place is summarized in Table 2.
Dosimetric considerations

Previous work has demonstrated that compliance with
TTFields and longer use lead to better outcomes, with
>90% usage leading to a median survival of 24.9 months
on an EF-14 subgroup analysis (16). Utilizing the device in
the setting of 6 weeks of daily treatment creates a logistical
challenge to achieve high level compliance (≥18 hours daily).
In addition, there are barriers to accepting TTFields from
a patient experience, with approximately 65% declining this
treatment due to personal reasons or lack of social support
when offered in both the primary and recurrent settings (17).
Lastly, daily removal and reapplication of the electrodes
to accommodate radiation treatments may increase skin
irritation, thus confounding skin toxicity outcomes. In
order to combat these challenges and provide an optimal

Removing and replacing the electrodes on a daily basis
during radiotherapy decreases the total time TTFields
can be used. One way to minimize this interruption, is
to deliver radiation treatment through TTFields arrays,
similar to what was performed in the aforementioned pilot
study. However, transducer arrays placed on the surface
of the patients receiving radiation can have dosimetric
effects. Li et al. investigated the delivery of radiotherapy
via volumetric-modulated-arc-therapy (VMAT) with and
without TTFields electrodes on the Anderson RANDO
phantom (18). The presence of the TTFields electrodes
created additional buildup effect that increased surface dose
(130–260%) directly underneath the probes. Attenuation
by the electrodes on deep dose measurements was of much
smaller magnitude, between 1–2%. A mean planning target
volume (PTV) dose reduction of 0.5–1% was observed, as
was a mean increase in scalp dose of 0.5–1 Gy. These results
demonstrate that tumor dose is unlikely to be compromised
due to blocking from the electrodes, however, care must be
given when evaluating skin dose. Although no significant
increase was observed in the treatment planning system
using commonly evaluated dose volume histogram (DVH)
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Figure 1 CT simulation both with (left) and without (right) TTFields arrays in place. On the left, there is increased artifact as a result of
array placement which can affect radiation dose calculation. CT, computed tomography; TTFields, tumor treating fields.

parameters in this study, scalp dose physical measurements
increased by a factor of 1.3–2.6 in open field and VMAT
deliveries.
The results of the aforementioned study are further
validated by additional work (19-21). Guberina et al.
showed that dose deviations in the clinical target volume
(CTV) were limited to a 2% underdosage due to transducer
arrays in 7 patients evaluated on a combined modality pilot
study (19). In addition, in comparison to a treatment plan
created without electrodes, scalp overdosage was limited to
8.5% of the prescribed dose in the first 2 mm below and in
deeper layers. Straube et al. utilized a RW3 slab phantom
and compared megavoltage (MV)-CT based planned dose
with measured dose (20). The group found attenuation
due to TTFields arrays was 3.4%, 3.7%, and 2.7% for
depths of 2, 3, and 4 cm, respectively. Dose conformity and
homogeneity were not affected by the TTFields arrays and
organs at risk (OAR) doses were only modestly affected
(increase or decrease by <0.5 Gy). Stachelek et al. found that
a slight bolus effect is observed with TTFields arrays (mean
increase in skin D 1 cc and D 20 cc of 3.1%) but that PTV
V97% and D97% were decreased by only 1.7% and 2.7%
or less, respectively (21). When arrays were repositioned,
dosimetric changes were minimized further.

When patients are planned for treatment through the
TTFields arrays, they are first simulated without these

arrays, in the supine position, utilizing a thermoplastic mask.
We recommend patients be simulated without TTFields
arrays for several reasons: (I) arrays can cause significant
CT artifact, and thus, radiation calculation is inaccurate
(Figure 1); (II) arrays will be shifted slightly throughout the
radiation course; (III) it avoids delay of radiation planning
due to waiting for array mapping and equipment delivery.
At the time of simulation, a custom low-density foam,
such as latex free open cell styrene butadiene rubber
(SBR) foam or 3M Reston self-adhering foam, is created
for the patient (Figure 2). For each patient, anterior and
posterior foam pads are created. The posterior foam pad
is first prepared by cutting 20 cm of length and adhering
to the head rest for support. Next, the anterior foam pad
is prepared by cutting 45–50 cm of length (can be adjusted
based on patient anatomy). Four separate triangles are then
cut in the anterior foam pad to allow for proper folding
and fitting over the head. The foam pad is then placed
over the patient’s head and adjusted for fit. The foam pad
should be kept above the ears. Once the foam is placed, the
thermoplastic mask should then be fitted to the patient and
allowed to conform over the foam. Once the mask is cooled
and firm, the foam is then adhered to the inside of the mask
for use during daily treatments. Since the foam has a low
density closely approximating that of air, there is minimum
bolus effect when used and no increase in scalp dose as a
result. The main purpose of the foam is to provide a space
between the head mask and patient, in order to better
accommodate the TTFields arrays.
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Figure 2 Foam cutouts created at the time of simulation demonstrated for two patients. Patients are simulated in the supine position with a
thermoplastic mask with underlying foam cutouts created to accommodate transducer arrays.

With regard to treatment, the power supply to TTFields
is discontinued before radiation and the device is left
outside treatment room. Each day of radiation treatment,
patients receive image-guided radiation therapy (IGRT) to
ensure proper positioning. Array shifts are possible during
the 6-week course of radiotherapy, however with IGRT, the
setup is reproducible and accurate, regardless of the absence
or presence of arrays, or with array position change. As
a result, for the days that patients are not wearing their
TTFields device, the setup can still be done correctly. Once
radiotherapy treatments are finished, the TTFields device is
reconnected and resumed promptly.

As demonstrated in global post-marketing safety
surveillance, the most common side effect of TTFields
is scalp irritation (22). For newly diagnosed GBM and
recurrent GBM, array-associated skin reaction occurred in
38% and 29% of patients, respectively. Other device-related
skin AEs include heat or electric sensations, pruritus,
hyperhidrosis, and in more severe cases, skin erosions/ulcers
(each ≤1%) and wound complications including dehiscence
and infection (≤1%). Given the known association with
radiation and skin dermatitis, it is important to minimize
overlapping scalp toxicity for the successful completion of
concurrent treatment.
Prophylactic interventions to minimize skin toxicity prior
to placement of TTFields arrays include optimal shaving to
maximize transducer-skin contact, removal of natural oils or
moisture from the scalp, regular transducer array changes

(at least 2 times per week), and regular array repositioning
to minimize direct pressure on the scalp and avoid surgical
scar lines (23). With regard to array shifts, they should be
shifted back to their original position to ensure optimal
targeting of the tumor bed (24). At every array change, the
skin and scalp should be assessed for signs and symptoms
of irritation and proper counseling should be provided in
order to maximize risk reduction.
If skin toxicities, including hyperhidrosis, dermatitis,
or ulcers, do develop despite these prophylactic measures,
then various management strategies can be performed. In
general, topical corticosteroids (included betamethasone
or clobetasol) can be used for irritant or contact dermatitis
with topic antibiotics (such as clindamycin or gentamicin)
reserved for skin ulcers and infection (25-27). Efforts should
be made to limit petroleum-based formulations of these
agents as they can affect electrical impedance of TTFields
(28-30). Attempts should be made to minimize treatment
breaks at the risk of compromising treatment outcomes.
In addition to these preventative and pharmacologic
interventions, another important measure is use advanced
radiation planning techniques to minimize scalp dose. We
recommend use VMAT scalp sparing planning. As a practical
means of taking scalp dose into account, total scalp is
defined as 5 mm thickness from skin surface above the level
of foramen magnum (Figure 3). The area between lateral
canthus, and below the orbital roof may be eliminated.
The scalp is then used as an avoidance structure for
planning, with the following dose constraints: mean <20 Gy
(acceptable <30 Gy), D20 cc <50 Gy (acceptable <55 Gy), and
D30 cc <40 Gy (acceptable <50 Gy) (18). Scalp constraints
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Figure 3 Total scalp structure contoured and displayed on axial (top left), coronal (bottom left), and sagittal (bottom right) cross sections. A
three-dimensional rendering of this structure is shown in the top left. Total scalp is defined as a 5 mm thick structure from skin surface above
the level of the foramen magnum and used for planning purposes.

may be violated to ensure adequate PTV coverage. On
the 30 patients pilot trial discussed previously, the mean
dose median was 8.3 Gy, the D20 cc median was 25.9 Gy,
and the D30 cc median was 23.5 Gy (3). From a practicality
perspective, these are minimum goals and lower doses are
frequently achievable. In order to assist with these goals,
the authors recommend identification of the bone plate on
CT. A 3 cm radial expansion of the bone plate should be
made with the overlying scalp from the outer bone plate to
skin surface defined as spared scalp. In addition, the CTV
should be modified to the inner plate of the calvarium to
make scalp sparing more feasible (Figure 4).

TTFields has led to significant improvements in outcome
for patients diagnosed with GBM. Previous work has
demonstrated the clinical benefit of administering this
therapy as maintenance and more recent work has shown
that concurrent administration is both feasible and offers

biologic synergy. Although tumor dosing does not appear
to be significantly affected by electrode array placement,
significant attention needs to be given to scalp dose
measurements to minimize toxicity. As discussed in this
review, a challenge of concurrent TTFields with radiation
is scalp dermatitis. Strategies including scalp structure
implementation in the planning process, as well as foam
cutouts at the time of CT simulation provide a means of
safely delivering treatment and future work should look
to further reduce toxicity through dosimetric means and
medical interventions during therapy. With the feasibility of
combined therapy established, current work is underway to
establish whether a clinical benefit exists. EF-32 is a phase 3,
randomized study (ClinicalTrials.gov: NCT04471844)
currently enrolling that is comparing chemoradiation with
TTFields vs. standard chemoradiation with a primary
endpoint of median OS and secondary endpoints including
median PFS and overall radiological response. With the
results of this trial, the potential clinical benefit of trimodality therapy will be established in patients with GBM.
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Sagittal

Coronal

Figure 4 Modification of CTV for a patient with GBM demonstrated on sagittal (left) and coronal (right) cross sections. The CTV is
modified to the inner plate of the calvarium (blue contour and purple contours) to assist with scalp sparing metrics. CTV, clinical target
volume; GBM, glioblastoma.
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